Available until 8/1/2024
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
featured
Use of Minoxidil in the Treatment of Alopecia Areata
abstract
This abstract is available on the publisher's site.
Access this abstract now Full Text Available for ClinicalKey SubscribersAlopecia Areata (AA) impacts approximately 2% of the global population. While the recent approval of two oral Janus Kinase inhibitors (JAKi) for the treatment of severe AA have transformed the therapeutic landscape, the efficacy of minoxidil as an adjunctive therapy for AA remains deserving of further exploration. This review aims to summarize current literature on minoxidil's efficacy in AA management.
Additional Info
Journal of the American Academy of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Use of Minoxidil in the Treatment of Alopecia Areata: A Systematic Review
J Am Acad Dermatol 2024 May 23;[EPub Ahead of Print], RS Raval, A Nohria, D Desai, K Mourtzanakis, M Buontempo, J Shapiro, K Lo SiccoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Combining minoxidil with oral Janus kinase inhibitors (JAKi) represents a promising approach in the control of alopecia areata. This combination may improve the potential of treatment of AA and enhance therapeutic outcomes.
This article makes the rationale behind the use of minoxidil as an adjacent therapy of JAKi in a comprehensive approach to hair restoration. A total of 595 out of 945 patients in three groups of articles studied showed the success rate in hair regrowth and relapse reduction when minoxidil and JAKi were combined. The combination may provide a superior alternative in comparison with monotherapy as well as facilitate the reduction of medication dosage and lower the risk of systemic side effects.
However, clinical studies evaluating the effectiveness and safety of combined minoxidil and JAKi are necessary to evaluate the potential of AA management. They should investigate specific parameters such as hair regrowth rate, disease control, and adverse effects to demonstrate to physicians the benefits of the combination in optimizing treatment outcomes.